Bellerophon Therapeutics Inc.

0.9200+0.0200+2.22%Vol 601.60K1Y Perf -82.86%
Jun 24th, 2022 16:00 DELAYED
BID0.8800 ASK1.15
Open0.8400 Previous Close0.9000
Pre-Market- After-Market1.10
 - -  0.18 19.57%
Target Price
24.50 
Analyst Rating
Strong Buy 1.00
Potential %
2.56K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.73 
Earnings Rating
Buy
Market Cap8.78M 
Earnings Date
4th Aug 2022
Alpha-0.03 Standard Deviation0.20
Beta-0.16 

Today's Price Range

0.84001.28

52W Range

0.67005.95

5 Year PE Ratio Range

-11.70-1.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
6.98%
1 Month
-3.77%
3 Months
-60.00%
6 Months
-68.92%
1 Year
-82.86%
3 Years
-90.71%
5 Years
-95.77%
10 Years
-

TickerPriceChg.Chg.%
BLPH0.92000.02002.22
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.55-0.59-7.27
Q04 2021-0.60-0.4525.00
Q03 2021-0.63-0.4922.22
Q02 2021-0.66-0.3645.45
Q01 2021-0.71-0.5818.31
Q04 2020--0.84-
Q03 2020-0.82-0.84-2.44
Q02 2020-0.68-0.5125.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.613.17Positive
9/2022 QR-0.5611.11Positive
12/2022 FY-2.318.33Positive
12/2023 FY-1.96--
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.61
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume601.60K
Shares Outstanding9.55K
Shares Float7.45M
Trades Count1.50K
Dollar Volume625.72K
Avg. Volume24.69K
Avg. Weekly Volume10.70K
Avg. Monthly Volume17.06K
Avg. Quarterly Volume46.32K

Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 0.92 per share at the end of the most recent trading day (a 2.22% change compared to the prior day closing price) with a volume of 601.60K shares and market capitalization of 8.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Bellerophon Therapeutics Inc. CEO is Fabian Tenenbaum.

The one-year performance of Bellerophon Therapeutics Inc. stock is -82.86%, while year-to-date (YTD) performance is -70.32%. BLPH stock has a five-year performance of -95.77%. Its 52-week range is between 0.67 and 5.95, which gives BLPH stock a 52-week price range ratio of 4.73%

Bellerophon Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.51, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -58.25%, a ROC of -69.57% and a ROE of -75.59%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Bellerophon Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Bellerophon Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Bellerophon Therapeutics Inc. is Strong Buy (1), with a target price of $24.5, which is +2 563.04% compared to the current price. The earnings rating for Bellerophon Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bellerophon Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bellerophon Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.19, ATR14 : 0.14, CCI20 : 45.98, Chaikin Money Flow : -0.46, MACD : -0.07, Money Flow Index : 83.78, ROC : -2.75, RSI : 41.75, STOCH (14,3) : 32.08, STOCH RSI : 0.92, UO : 36.57, Williams %R : -67.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bellerophon Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension.

CEO: Fabian Tenenbaum

Telephone: +1 908 574-4770

Address: 184 Liberty Corner Road, Warren 07059, NJ, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

66%34%

Bearish Bullish

59%41%

News

Stocktwits